Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Subscribe To Our Newsletter & Stay Updated
